Patent · US Active

Progesterone formulations having a desirable PK profile

US10471148B2 · kind B2 · utility

5Cited by

561References

32Claims

0Family size

Assignee

Compass Therapeutics LLC · US

Inventors

Janice Louise Cacace · St. Petersburg, US
Peter H. R. Persicaner · Boca Raton, US
Thorsteinn Thorsteinsson · Boynton Beach, US
Frederick D. Sancilio · North Palm Beach, US
Julia M. Amadio · Boca Raton, US
Brian A. Bernick · Boca Raton, US

Key dates

Filing date	Mar 9, 2017
Grant date	Nov 12, 2019
Priority date	—
Expiry date	Mar 9, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/57
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.